JPRN-jRCT2080221787
Unknown
Phase 2
An open-label, long-term extension study to evaluate the safety, tolerability and efficacy of 12 months of LCZ696 treatment in patients with essential hypertension
ovartis Pharma K.K.0 sites344 target enrollmentMay 14, 2012
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- ovartis Pharma K.K.
- Enrollment
- 344
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients that have successfully completed Core study (JapicCTI\-101273\) and who, as judged by the investigator, are able to continue in the open\-label extension.
- •2\. Ability to communicate and comply with all study requirements and demonstrate good medication compliance (\>\=80% compliance rate) during Core study.
Exclusion Criteria
- •1\. Patients who did not complete Core study.
- •2\. Presence of significant protocol violation in Core study.
- •3\. Patients who are deemed to be unable to comply with the protocol by the investigator.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
An open label, long-term extension study to evaluate the safety and efficacy of CRN00808 in subjects with acromegaly (ACROBAT ADVANCE)AcromegalyMedDRA version: 20.0Level: PTClassification code: 10000599Term: Acromegaly Class: 100000004860Therapeutic area: Diseases [C] - Hormonal diseases [C19]CTIS2024-511921-75-00Crinetics Pharmaceuticals Inc.31
Unknown
Phase 3
Venlafaxine ER long-term extension study for major depressive disorderJPRN-jRCT2080221669Pfizer Japan Inc.50
Active, not recruiting
Phase 2
A 5-year study to test BI 655130 in patients with Generalized Pustular Psoriasis who took part in previous studies with BI 655130Generalized Pustular Psoriasis (GPP)JPRN-jRCT2041210087Taguchi Aya131
Active, not recruiting
Phase 1
A 5-year study to test BI 655130 in patients with GeneralizedPustular Psoriasis who took part in previous studies with BI655130Generalized Pustular PsoriasisMedDRA version: 21.0Level: LLTClassification code 10037159Term: Psoriasis pustularSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2018-003080-56-ESBoehringer Ingelheim España S.A.150
Active, not recruiting
Phase 1
A 5-year study to test BI 655130 in patients with Generalized Pustular Psoriasis who took part in previous studies with BI 655130EUCTR2018-003080-56-FRBoehringer Ingelheim France101